Clinical Trial Update: A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations [Phase 3]

View source ↗

Summary

Announcement of a Phase III trial evaluating HS-20093 injection plus adebrelimab versus docetaxel in previously treated advanced or metastatic non-squamous non-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)
• DOCETAXEL (DOCETAXEL)
• HS-20093 injection

Snippet

Sponsor: Hansoh BioMedical R&D Company | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: NOT_YET_RECRUITING